JP6092226B2 - Ｇｃｇｒ発現のアンチセンス調整 - Google Patents
Ｇｃｇｒ発現のアンチセンス調整 Download PDFInfo
- Publication number
- JP6092226B2 JP6092226B2 JP2014531947A JP2014531947A JP6092226B2 JP 6092226 B2 JP6092226 B2 JP 6092226B2 JP 2014531947 A JP2014531947 A JP 2014531947A JP 2014531947 A JP2014531947 A JP 2014531947A JP 6092226 B2 JP6092226 B2 JP 6092226B2
- Authority
- JP
- Japan
- Prior art keywords
- certain embodiments
- compound
- seq
- isis
- gcgr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1(C(*)(C(*)(C(*)(*)OC2(C(*C=I)([N+]([O-])=O)OC)O)O)C2(*)OC)IC1 Chemical compound C*1(C(*)(C(*)(C(*)(*)OC2(C(*C=I)([N+]([O-])=O)OC)O)O)C2(*)OC)IC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161537007P | 2011-09-20 | 2011-09-20 | |
| US61/537,007 | 2011-09-20 | ||
| PCT/US2012/056249 WO2013043817A1 (en) | 2011-09-20 | 2012-09-20 | Antisense modulation of gcgr expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017020906A Division JP6538736B2 (ja) | 2011-09-20 | 2017-02-08 | Ｇｃｇｒ発現のアンチセンス調整 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530004A JP2014530004A (ja) | 2014-11-17 |
| JP2014530004A5 JP2014530004A5 (OSRAM) | 2015-02-05 |
| JP6092226B2 true JP6092226B2 (ja) | 2017-03-08 |
Family
ID=47914848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014531947A Active JP6092226B2 (ja) | 2011-09-20 | 2012-09-20 | Ｇｃｇｒ発現のアンチセンス調整 |
| JP2017020906A Active JP6538736B2 (ja) | 2011-09-20 | 2017-02-08 | Ｇｃｇｒ発現のアンチセンス調整 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017020906A Active JP6538736B2 (ja) | 2011-09-20 | 2017-02-08 | Ｇｃｇｒ発現のアンチセンス調整 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8865674B2 (OSRAM) |
| EP (2) | EP2758533B1 (OSRAM) |
| JP (2) | JP6092226B2 (OSRAM) |
| KR (1) | KR101840512B1 (OSRAM) |
| CN (2) | CN108410868A (OSRAM) |
| AU (2) | AU2012312433B2 (OSRAM) |
| BR (1) | BR112014006587B1 (OSRAM) |
| CA (1) | CA2849273C (OSRAM) |
| DK (1) | DK2758533T3 (OSRAM) |
| ES (2) | ES2796556T3 (OSRAM) |
| IL (1) | IL231560B (OSRAM) |
| IN (1) | IN2014CN02736A (OSRAM) |
| MX (1) | MX353322B (OSRAM) |
| NO (1) | NO2925947T3 (OSRAM) |
| RU (1) | RU2598709C2 (OSRAM) |
| WO (1) | WO2013043817A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3330278A1 (en) | 2012-02-08 | 2018-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| MX373283B (es) | 2014-05-01 | 2020-05-20 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento. |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| AR101449A1 (es) * | 2014-08-04 | 2016-12-21 | Miragen Therapeutics Inc | Inhibidores de myh7b y usos de los mismos |
| WO2016141236A1 (en) * | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
| CN107614695B (zh) * | 2015-04-02 | 2022-01-25 | 瑞美德生物医药科技有限公司 | 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法 |
| JP6833705B2 (ja) * | 2015-04-03 | 2021-02-24 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
| CN108026529A (zh) * | 2015-09-30 | 2018-05-11 | Ionis制药公司 | 组合疗法 |
| JP7173962B2 (ja) | 2016-08-30 | 2022-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法 |
| CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| CN108174843B (zh) * | 2018-01-24 | 2018-11-13 | 广州市进德生物科技有限公司 | 一种胰高血糖素保护剂及其应用 |
| JP7530106B2 (ja) * | 2019-03-14 | 2024-08-07 | レナセラピューティクス株式会社 | Ｉｈｈ発現を調節するための核酸複合体 |
| IL319629A (en) | 2022-09-23 | 2025-05-01 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing MECP2 expression |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| WO1992017611A1 (en) | 1991-03-28 | 1992-10-15 | The University Of Tennessee Research Corporation | Dna silver staining |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| JPH06508622A (ja) | 1991-06-18 | 1994-09-29 | テンプル ユニバーシティ−オブ ザ コモンウェルス システム オブ ハイヤーエデュケーション | ｂｃｒ−ａｂ１アンチセンスオリゴヌクレオチドによる白血球増殖の選択的抑制 |
| DE69225227T2 (de) | 1991-06-27 | 1998-10-29 | Genelabs Tech Inc | Screeningtest für den nachweis von dna-bindenden molekülen |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| US5804383A (en) | 1992-08-21 | 1998-09-08 | The Regents Of The University Of California | Method and assay for detection of the expression of allele-specific mutations by allele-specific in situ reverse transcriptase polymerase chain reaction |
| HU219674B (hu) | 1992-08-28 | 2001-06-28 | Novo Nordisk A/S | Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra |
| US5776725A (en) | 1992-08-28 | 1998-07-07 | Zymogenetics, Inc. | Recombinant production of glucagon receptors |
| US5985558A (en) | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| US6410324B1 (en) | 2001-04-27 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of tumor necrosis factor receptor 2 expression |
| US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
| US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
| EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
| WO1994025588A2 (en) | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
| US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5563036A (en) | 1994-04-29 | 1996-10-08 | Tularik, Inc. | Transcription factor-DNA binding assay |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5612455A (en) | 1994-07-05 | 1997-03-18 | Tularik, Inc. | Nuclear factors and binding assay |
| US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US6251873B1 (en) | 1997-03-07 | 2001-06-26 | Mochida Pharmaceutical Co., Ltd. | Antisense compounds to CD14 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| WO1999014226A2 (en) | 1997-09-12 | 1999-03-25 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| WO1999015643A2 (en) | 1997-09-25 | 1999-04-01 | University Of Florida | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE |
| US20030203862A1 (en) | 1998-03-26 | 2003-10-30 | Miraglia Loren J. | Antisense modulation of MDM2 expression |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| AU767568B2 (en) | 1998-07-23 | 2003-11-13 | Gen-Probe Incorporated | Methods for detecting and measuring spliced nucleic acids |
| US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| US5962673A (en) * | 1998-11-20 | 1999-10-05 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-alpha expression |
| US20030087854A1 (en) | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| US6692959B2 (en) | 1998-11-25 | 2004-02-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of IL-1 receptor-associated kinase-4 expression |
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6492152B1 (en) | 1999-06-15 | 2002-12-10 | The Board Of Regents Of The University Of Oklahoma | Core 1 β3-galactosyl transferases and methods of use thereof |
| US6284538B1 (en) * | 1999-07-21 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTEN expression |
| JP2003516151A (ja) | 1999-11-29 | 2003-05-13 | エイブイアイ バイオファーマ， インコーポレイテッド | 細菌１６Ｓおよび２３ＳｒＲＮＡに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用 |
| US6869762B1 (en) * | 1999-12-10 | 2005-03-22 | Whitehead Institute For Biomedical Research | Crohn's disease-related polymorphisms |
| US20020055479A1 (en) * | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| US6602857B1 (en) * | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US6770486B1 (en) | 2000-02-08 | 2004-08-03 | Isis Pharmaceuticals, Inc. | Optimization of ligand affinity for RNA targets using mass spectrometry |
| US20040241651A1 (en) | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| WO2001092524A2 (en) | 2000-05-26 | 2001-12-06 | Aeomica, Inc. | Myosin-like gene expressed in human heart and muscle |
| IL154473A0 (en) | 2000-08-18 | 2003-09-17 | Proskelia | Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| AU2001296412A1 (en) | 2000-09-29 | 2002-04-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of mekk4 expression |
| WO2002045494A2 (en) | 2000-12-06 | 2002-06-13 | Deltagen, Inc. | Transgenic mice containing glucagon receptor gene disruptions |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| US7759545B2 (en) | 2002-06-06 | 2010-07-20 | Monsanto Technology Llc | Methods and compositions for production of maize lines with increased transformability |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| KR20050088196A (ko) * | 2002-12-19 | 2005-09-02 | 알자 코포레이션 | 안정한 비수성 단일 상 겔 및 이식가능한 장치로부터전달하기 위한 이의 제형 |
| US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| US7750142B2 (en) | 2003-04-28 | 2010-07-06 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| US20050142581A1 (en) | 2003-09-04 | 2005-06-30 | Griffey Richard H. | Microrna as ligands and target molecules |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| EP1706489B9 (en) | 2003-12-23 | 2011-01-05 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
| US7341835B2 (en) * | 2004-01-13 | 2008-03-11 | Affymetrix, Inc. | Methods of analysis of alternative splicing in mouse |
| US7943754B2 (en) * | 2004-04-02 | 2011-05-17 | Rosetta-Genomics | Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| EP2388326A1 (en) * | 2005-09-19 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| CN101489565A (zh) * | 2006-05-05 | 2009-07-22 | Isis药物公司 | 调节pcsk9表达的化合物和方法 |
| EP2505646A1 (en) * | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| NZ585250A (en) * | 2007-11-09 | 2012-06-29 | Isis Pharmaceuticals Inc | Antisense modulation of factor 7 expression |
| EP2222851B1 (en) * | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
| US11511972B1 (en) | 2019-09-26 | 2022-11-29 | Versatile, Inc. | System for tracking lifting events at a construction site |
-
2012
- 2012-09-20 EP EP12834215.1A patent/EP2758533B1/en active Active
- 2012-09-20 KR KR1020147007766A patent/KR101840512B1/ko active Active
- 2012-09-20 IN IN2736CHN2014 patent/IN2014CN02736A/en unknown
- 2012-09-20 WO PCT/US2012/056249 patent/WO2013043817A1/en not_active Ceased
- 2012-09-20 EP EP18166477.2A patent/EP3401401B1/en active Active
- 2012-09-20 MX MX2014003492A patent/MX353322B/es active IP Right Grant
- 2012-09-20 CA CA2849273A patent/CA2849273C/en active Active
- 2012-09-20 JP JP2014531947A patent/JP6092226B2/ja active Active
- 2012-09-20 BR BR112014006587-0A patent/BR112014006587B1/pt active IP Right Grant
- 2012-09-20 CN CN201810052777.0A patent/CN108410868A/zh active Pending
- 2012-09-20 ES ES18166477T patent/ES2796556T3/es active Active
- 2012-09-20 US US13/623,337 patent/US8865674B2/en active Active
- 2012-09-20 DK DK12834215.1T patent/DK2758533T3/en active
- 2012-09-20 CN CN201280045717.7A patent/CN103814132B/zh active Active
- 2012-09-20 ES ES12834215.1T patent/ES2673721T3/es active Active
- 2012-09-20 RU RU2014115215/10A patent/RU2598709C2/ru active
- 2012-09-20 AU AU2012312433A patent/AU2012312433B2/en active Active
-
2013
- 2013-08-22 NO NO13752632A patent/NO2925947T3/no unknown
-
2014
- 2014-03-17 IL IL231560A patent/IL231560B/en active IP Right Grant
- 2014-09-12 US US14/484,638 patent/US9404114B2/en active Active
-
2017
- 2017-02-08 JP JP2017020906A patent/JP6538736B2/ja active Active
- 2017-09-26 AU AU2017235886A patent/AU2017235886B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6092226B2 (ja) | Ｇｃｇｒ発現のアンチセンス調整 | |
| US9567587B2 (en) | Antisense modulation of GCCR expression | |
| EP2721156B1 (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
| JP2013527148A (ja) | Ｃｅｔｐ発現の調節 | |
| JP5951752B2 (ja) | Ｐｔｐ１ｂ発現のアンチセンス調節 | |
| HK1201070B (en) | Antisense modulation of gcgr expression | |
| NZ622398B2 (en) | Antisense modulation of gcgr expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160909 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6092226 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |